PURPOSE: This report examines cognitive complaints and neuropsychological (NP) testing outcomes in @entity1 with @entity0 after the initiation of endocrine therapy (ET) to determine whether this therapy plays any role in post-treatment cognitive complaints. @entity1 AND METHODS: One hundred seventy-three @entity1 from the @entity1053 ( @entity1053 ) observational cohort provided data from self-report questionnaires and NP testing obtained at enrollment (T1, before initiation of ET), and 6 months later (T2). Bivariate analyses compared demographic and treatment variables, cognitive complaints, @entity308 , quality of life, and NP functioning between those who received ET versus not. Multivariable linear regression models examined @entity73 at T2, including selected demographic variables, @entity308 , ET use, and other medical variables, along with NP domains that were identified in bivariate analyses. RESULTS: Seventy percent of the 173 @entity1053 @entity1 initiated ET, evenly distributed between @entity440 or aromatase inhibitors. ET-treated @entity1 reported significantly increased language and communication (LC) cognitive complaints at T2 (P = .003), but no significant differences in NP test performance. Multivariable regression on LC at T2 found higher LC complaints significantly associated with T1 LC score (P < .001), ET at T2 (P = .004), interaction between ET and past @entity34 ( @entity34 ) (P < .001), and diminished improvement in NP psychomotor function (P = .05). @entity308 were not significant (P = .10). CONCLUSION: Higher LC complaints are significantly associated with ET 6 months after starting treatment and reflect diminished improvements in some NP tests. Past @entity34 is a significant predictor of higher LC complaints after initiation of ET.

Cognitive function after the initiation of adjuvant endocrine therapy in XXXX : an observational cohort study.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'PATIENTS'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms', 'Depressive symptoms'] @entity0 :: ('MESH:D001943', 'Disease') :: ['early-stage breast cancer'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity73 :: ('MESH:D003072', 'Disease') :: ['predictors of cognitive complaints'] @entity1053 :: ('MESH:D001835', 'Disease') :: ['MBS', 'Mind Body Study'] @entity34 :: ('MESH:D016609', 'Disease') :: ['hormone therapy', 'HT']
@entity0 :: (MESH:D001943,Disease) :: ['early-stage breast cancer']
